nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—Retinoid metabolism and transport—AKR1B10—uterine cancer	0.0806	0.111	CbGpPWpGaD
Tyloxapol—LPL—decidua—uterine cancer	0.0568	0.206	CbGeAlD
Tyloxapol—LPL—renal system—uterine cancer	0.0558	0.202	CbGeAlD
Tyloxapol—LPL—Retinoid metabolism and transport—AKR1C1—uterine cancer	0.055	0.076	CbGpPWpGaD
Tyloxapol—LPL—mammalian vulva—uterine cancer	0.0522	0.189	CbGeAlD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.0461	0.0637	CbGpPWpGaD
Tyloxapol—LPL—female reproductive system—uterine cancer	0.0447	0.162	CbGeAlD
Tyloxapol—LPL—Retinoid metabolism and transport—AKR1C3—uterine cancer	0.0423	0.0585	CbGpPWpGaD
Tyloxapol—LPL—Diseases associated with visual transduction—AKR1B10—uterine cancer	0.0411	0.0568	CbGpPWpGaD
Tyloxapol—LPL—female gonad—uterine cancer	0.0406	0.147	CbGeAlD
Tyloxapol—LPL—Alzheimers Disease—MME—uterine cancer	0.034	0.0469	CbGpPWpGaD
Tyloxapol—LPL—Diseases associated with visual transduction—AKR1C1—uterine cancer	0.0281	0.0388	CbGpPWpGaD
Tyloxapol—LPL—lymph node—uterine cancer	0.0261	0.0946	CbGeAlD
Tyloxapol—LPL—Diseases associated with visual transduction—AKR1C3—uterine cancer	0.0216	0.0299	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.0201	0.0277	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—HMGA1—uterine cancer	0.0164	0.0226	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—PLXNA3—uterine cancer	0.0159	0.0219	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.0137	0.0189	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.0126	0.0175	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—SOCS3—uterine cancer	0.0123	0.0169	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.012	0.0166	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.0114	0.0157	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.0112	0.0155	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—SMAD3—uterine cancer	0.0107	0.0148	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.00965	0.0133	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00913	0.0126	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00913	0.0126	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—HNF1B—uterine cancer	0.00834	0.0115	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.0082	0.0113	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—EP300—uterine cancer	0.00794	0.011	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.0067	0.00926	CbGpPWpGaD
Tyloxapol—LPL—SREBP signalling—PIK3CA—uterine cancer	0.00641	0.00886	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NDUFB11—uterine cancer	0.00563	0.00777	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SRD5A2—uterine cancer	0.00563	0.00777	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—CTNNB1—uterine cancer	0.00562	0.00776	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—TP53—uterine cancer	0.00557	0.00769	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.00546	0.00755	CbGpPWpGaD
Tyloxapol—LPL—SREBP signalling—AKT1—uterine cancer	0.00524	0.00724	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKR1B10—uterine cancer	0.00522	0.00722	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.00516	0.00713	CbGpPWpGaD
Tyloxapol—LPL—Disease—RNF43—uterine cancer	0.00433	0.00598	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—STAR—uterine cancer	0.00407	0.00562	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKR1B1—uterine cancer	0.00407	0.00562	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.00402	0.00555	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—SMAD3—uterine cancer	0.00368	0.00509	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKR1B10—uterine cancer	0.00366	0.00505	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKR1C1—uterine cancer	0.00356	0.00492	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—POLD1—uterine cancer	0.00319	0.00441	CbGpPWpGaD
Tyloxapol—LPL—Disease—DCN—uterine cancer	0.00308	0.00426	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—RNF43—uterine cancer	0.00303	0.00419	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MET—uterine cancer	0.00302	0.00417	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKR1C1—uterine cancer	0.00299	0.00412	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—INHBA—uterine cancer	0.00277	0.00383	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKR1C3—uterine cancer	0.00274	0.00379	CbGpPWpGaD
Tyloxapol—LPL—Disease—HMGA1—uterine cancer	0.00267	0.00369	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—RRM2—uterine cancer	0.00266	0.00368	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—DCN—uterine cancer	0.00258	0.00357	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKR1C1—uterine cancer	0.0025	0.00345	CbGpPWpGaD
Tyloxapol—LPL—Disease—FBXW7—uterine cancer	0.00245	0.00338	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP11A1—uterine cancer	0.00243	0.00336	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKR1C3—uterine cancer	0.0023	0.00318	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—ERBB2—uterine cancer	0.00221	0.00305	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CTNNB1—uterine cancer	0.00193	0.00267	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKR1C3—uterine cancer	0.00192	0.00265	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN2B—uterine cancer	0.00192	0.00265	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PGR—uterine cancer	0.00187	0.00259	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—EP300—uterine cancer	0.00179	0.00248	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—STK11—uterine cancer	0.00179	0.00247	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP19A1—uterine cancer	0.00179	0.00247	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—YWHAE—uterine cancer	0.00179	0.00247	CbGpPWpGaD
Tyloxapol—LPL—Disease—SMAD3—uterine cancer	0.00175	0.00242	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FBXW7—uterine cancer	0.00171	0.00237	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—VEGFA—uterine cancer	0.0017	0.00235	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.00168	0.00232	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—NRAS—uterine cancer	0.00168	0.00232	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGFR2—uterine cancer	0.00167	0.00231	CbGpPWpGaD
Tyloxapol—LPL—Disease—MTHFR—uterine cancer	0.00161	0.00222	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.0016	0.00221	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—STK11—uterine cancer	0.0015	0.00207	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—KRAS—uterine cancer	0.00145	0.002	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SOCS3—uterine cancer	0.0014	0.00194	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—MTHFR—uterine cancer	0.00135	0.00186	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN2B—uterine cancer	0.00134	0.00185	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IGF1R—uterine cancer	0.0013	0.0018	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—HRAS—uterine cancer	0.00123	0.0017	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SMAD3—uterine cancer	0.00123	0.00169	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	0.00119	0.00164	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGFR2—uterine cancer	0.00117	0.00161	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—AKT1—uterine cancer	0.00108	0.0015	CbGpPWpGaD
Tyloxapol—LPL—Disease—ERBB2—uterine cancer	0.00105	0.00145	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ESR1—uterine cancer	0.001	0.00138	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN1B—uterine cancer	0.000971	0.00134	CbGpPWpGaD
Tyloxapol—LPL—Disease—CTNNB1—uterine cancer	0.000917	0.00127	CbGpPWpGaD
Tyloxapol—LPL—Disease—PTEN—uterine cancer	0.000894	0.00123	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCL2—uterine cancer	0.00088	0.00122	CbGpPWpGaD
Tyloxapol—LPL—Disease—EP300—uterine cancer	0.000852	0.00118	CbGpPWpGaD
Tyloxapol—LPL—Disease—NRAS—uterine cancer	0.000797	0.0011	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PTEN—uterine cancer	0.000748	0.00103	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ERBB2—uterine cancer	0.000734	0.00101	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—EP300—uterine cancer	0.000714	0.000986	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL8—uterine cancer	0.000696	0.000962	CbGpPWpGaD
Tyloxapol—LPL—Disease—KRAS—uterine cancer	0.000686	0.000948	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN1B—uterine cancer	0.00068	0.000939	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CTNNB1—uterine cancer	0.000642	0.000887	CbGpPWpGaD
Tyloxapol—LPL—Disease—PIK3CA—uterine cancer	0.000631	0.000871	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PTEN—uterine cancer	0.000626	0.000865	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EP300—uterine cancer	0.000597	0.000825	CbGpPWpGaD
Tyloxapol—LPL—Disease—HRAS—uterine cancer	0.000583	0.000806	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VEGFA—uterine cancer	0.000565	0.000781	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NRAS—uterine cancer	0.000558	0.000771	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CA—uterine cancer	0.000528	0.00073	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKT1—uterine cancer	0.000515	0.000712	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KRAS—uterine cancer	0.000481	0.000664	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CA—uterine cancer	0.000442	0.00061	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKT1—uterine cancer	0.000431	0.000596	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TP53—uterine cancer	0.000427	0.00059	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HRAS—uterine cancer	0.000408	0.000564	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKT1—uterine cancer	0.000361	0.000498	CbGpPWpGaD
